Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
79,376,583
-
Total 13F shares
-
31,507,544
-
Share change
-
+661,936
-
Total reported value
-
$913,643,371
-
Put/Call ratio
-
800%
-
Price per share
-
$29.01
-
Number of holders
-
109
-
Value change
-
+$20,106,775
-
Number of buys
-
50
-
Number of sells
-
40
Institutional Holders of Akero Therapeutics, Inc. - COMMON STOCK (AKRO) as of Q1 2021
As of 31 Mar 2021,
Akero Therapeutics, Inc. - COMMON STOCK (AKRO) was held by
109 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,507,544 shares.
The largest 10 holders included
ATP Life Science Ventures, L.P., JANUS HENDERSON GROUP PLC, Redmile Group, LLC, ALKEON CAPITAL MANAGEMENT LLC, venBio Partners LLC, HILLHOUSE CAPITAL ADVISORS, LTD., WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., VANGUARD GROUP INC, and STATE STREET CORP.
This page lists
109
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.